003520 — Yungjin Pharm Co Share Price
0.000.00%
Last trade - 00:00- KR₩335bn
- KR₩385bn
- KR₩235bn
- 59
- 15
- 15
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.64 | ||
| Price to Tang. Book | 3.71 | ||
| Price to Free Cashflow | 107.47 | ||
| Price to Sales | 1.32 | ||
| EV to EBITDA | 27.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.49% | ||
| Return on Equity | 1.15% | ||
| Operating Margin | 2.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 220,516.29 | 208,463.64 | 196,067.24 | 218,380.99 | 234,902.46 | n/a | n/a | 4.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yungjin Pharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including antibiotics, respiratory drugs, anti-infective drugs, antipyretics, analgesics, central nervous system (CNS) drugs, gastrointestinal (GI) drugs, cardiovascular (CV) drugs, antihistamines, antifungals, antidiabetics, vitamin nutrients, antibiotic raw materials, and others. The Company also engages in the leasing of real estates.
Directors
- Su Jun Park CEO (52)
- Geon Tae Kim DRC (51)
- Jong Du Kim NID (63)
- Seung Wung Lee NID (72)
- Yeong Jak Lee NID (73)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- July 16th, 1962
- Public Since
- June 25th, 1973
- No. of Shareholders
- 90,850
- No. of Employees
- 636
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 182,892,454
- Address
- 13, Olympic-ro 35da-gil, Songpa-gu, SEOUL, 05510
- Web
- http://www.yungjin.co.kr/
- Phone
- +82 220418200
- Auditors
- Ernst & Young Han Young
Upcoming Events for 003520
Yungjin Pharm Co Ltd Annual Shareholders Meeting
Q1 2025 Yungjin Pharm Co Ltd Earnings Release
Similar to 003520
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Yungjin Pharm Co share price?
As of Today at 23:14 UTC, shares in Yungjin Pharm Co are trading at KR₩1,832. This share price information is delayed by 15 minutes.
How has the Yungjin Pharm Co share price performed this year?
Shares in Yungjin Pharm Co last closed at KR₩1,832 and the price had moved by -9.13% over the past 365 days. In terms of relative price strength the Yungjin Pharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -13.66% over the past year.
What are the analyst and broker recommendations for Yungjin Pharm Co?
There is no consensus recommendation for this security.
Find out moreWhat is the Yungjin Pharm Co dividend yield?
Yungjin Pharm Co does not currently pay a dividend.
Does Yungjin Pharm Co pay a dividend?
Yungjin Pharm Co does not currently pay a dividend.
When does Yungjin Pharm Co next pay dividends?
Yungjin Pharm Co does not currently pay a dividend.
How do I buy Yungjin Pharm Co shares?
To buy shares in Yungjin Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Yungjin Pharm Co?
As of the previous close price of KR₩1,832, shares in Yungjin Pharm Co had a market capitalisation of KR₩335bn.
Where are Yungjin Pharm Co shares listed?
Here are the trading details for Yungjin Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 003520
What kind of share is Yungjin Pharm Co?
Based on an overall assessment of its quality, value and momentum Yungjin Pharm Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Yungjin Pharm Co share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Yungjin Pharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yungjin Pharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -19.56%.
As of the last closing price of KR₩1,832, shares in Yungjin Pharm Co were trading -17.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Yungjin Pharm Co PE Ratio?
The Yungjin Pharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩1,832.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Yungjin Pharm Co?
Yungjin Pharm Co's management team is headed by:
- Su Jun Park - CEO
- Geon Tae Kim - DRC
- Jong Du Kim - NID
- Seung Wung Lee - NID
- Yeong Jak Lee - NID